D. Boral Capital reiterated their buy rating on shares of Immunic (NASDAQ:IMUX – Free Report) in a r...
Immunic, Inc. (NASDAQ:IMUX – Free Report) – Equities research analysts at Leerink Partnrs lifted the...
Immunic, Inc. (NASDAQ:IMUX - Get Free Report) CEO Daniel Vitt bought 15,000 shares of the stock in a...
Clinical updates, including trial initiations, enrollment status and data readouts and publications:...